AU2019253028B2 - A2-73 crystalline polymorph compositions of matter and methods of use thereof - Google Patents

A2-73 crystalline polymorph compositions of matter and methods of use thereof Download PDF

Info

Publication number
AU2019253028B2
AU2019253028B2 AU2019253028A AU2019253028A AU2019253028B2 AU 2019253028 B2 AU2019253028 B2 AU 2019253028B2 AU 2019253028 A AU2019253028 A AU 2019253028A AU 2019253028 A AU2019253028 A AU 2019253028A AU 2019253028 B2 AU2019253028 B2 AU 2019253028B2
Authority
AU
Australia
Prior art keywords
anavex2
xrpd pattern
freebase
crystalline
rule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019253028A
Other languages
English (en)
Other versions
AU2019253028A1 (en
Inventor
Christopher U. Missling
Alani SELVEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of AU2019253028A1 publication Critical patent/AU2019253028A1/en
Application granted granted Critical
Publication of AU2019253028B2 publication Critical patent/AU2019253028B2/en
Priority to AU2024205423A priority Critical patent/AU2024205423B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
AU2019253028A 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof Active AU2019253028B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205423A AU2024205423B2 (en) 2018-04-12 2024-08-02 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656435P 2018-04-12 2018-04-12
US62/656,435 2018-04-12
PCT/US2019/027369 WO2019200345A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205423A Division AU2024205423B2 (en) 2018-04-12 2024-08-02 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019253028A1 AU2019253028A1 (en) 2020-10-15
AU2019253028B2 true AU2019253028B2 (en) 2024-05-30

Family

ID=68163817

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019253028A Active AU2019253028B2 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof
AU2024205423A Active AU2024205423B2 (en) 2018-04-12 2024-08-02 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205423A Active AU2024205423B2 (en) 2018-04-12 2024-08-02 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Country Status (7)

Country Link
US (3) US11498908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773531A4 (cg-RX-API-DMAC7.html)
JP (4) JP7532718B2 (cg-RX-API-DMAC7.html)
CN (1) CN112105349A (cg-RX-API-DMAC7.html)
AU (2) AU2019253028B2 (cg-RX-API-DMAC7.html)
CA (2) CA3096671C (cg-RX-API-DMAC7.html)
WO (1) WO2019200345A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
JP2025514292A (ja) * 2022-04-29 2025-05-02 ▲蘇▼州科睿思制▲葯▼有限公司 塩酸ブラルカメシンの結晶形、その調製方法およびその使用
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030983A1 (en) * 1996-02-21 1997-08-28 Alexandre Vamvakides Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
WO2017013498A2 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
GR1008233B (el) * 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030983A1 (en) * 1996-02-21 1997-08-28 Alexandre Vamvakides Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts
WO2017013498A2 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOSCOLOS, G. B. ET AL., "Synthesis and pharmacological study of some new β-(dialkylaminomethyl)-γ-butyrolactones and their tetrahydrofuran analogs", Farmaco, 1996, Vol. 51(1), pages19-26 *

Also Published As

Publication number Publication date
JP2021521188A (ja) 2021-08-26
AU2024205423B2 (en) 2026-06-25
JP2025131907A (ja) 2025-09-09
US20230142424A1 (en) 2023-05-11
US11498908B2 (en) 2022-11-15
JP7532718B2 (ja) 2024-08-14
EP3773531A4 (en) 2021-06-23
AU2019253028A1 (en) 2020-10-15
CA3256071A1 (en) 2025-10-31
US12180174B2 (en) 2024-12-31
AU2024205423A1 (en) 2024-08-22
US20250115566A1 (en) 2025-04-10
JP2024038524A (ja) 2024-03-19
JP7758768B2 (ja) 2025-10-22
EP3773531A1 (en) 2021-02-17
US20210115004A1 (en) 2021-04-22
JP2026004574A (ja) 2026-01-14
CA3096671A1 (en) 2019-10-17
WO2019200345A1 (en) 2019-10-17
CN112105349A (zh) 2020-12-18
CA3096671C (en) 2025-09-16

Similar Documents

Publication Publication Date Title
US12180174B2 (en) A2-73 crystalline polymorph compositions of matter and methods of use thereof
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
EP2753613B1 (en) Derivatives of xanthone compounds
EP3365323B1 (en) Salts of tetracyclines
EP3393457A1 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
CA3086611C (en) A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
WO2019196955A1 (zh) R 10与r 11连接的亲水性小檗碱型衍生物及其制备药物的应用
EA019689B1 (ru) Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения
US8471044B2 (en) Epigallocatechin-3-gallate crystal compositions
CN110035745A (zh) 小分子ampk活化剂
CN100445288C (zh) 银杏内酯b衍生物及其在制药中的应用
US12098134B2 (en) Benzo-heterocyclic compound and composition for preventing or treating cancer disease, containing same as active ingredient
AU2022339672B2 (en) Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph
KR101714259B1 (ko) 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물(2)
US9776989B2 (en) Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
KR102509190B1 (ko) 트리메부틴 말레산염의 다형체 및 이의 사용방법
KR20180124428A (ko) 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20180124400A (ko) 사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물
CN119997948A (zh) 用于预防退行性疾病引起的认知下降的组合物和方法
KR20160146428A (ko) 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR20110126132A (ko) 4,6-디클로로-1η-인돌-2-카르복실산 유도체 또는 이의 염을 유효 성분으로서 함유하는 시신경 장애의 예방 또는 치료제
WO2019120111A1 (zh) 二甲双胍盐在治疗脑梗死中的用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MISSLING, CHRISTOPHER U. AND SELVEY, ALANI

FGA Letters patent sealed or granted (standard patent)